8-K: ENDRA Life Sciences Reports Reduced Losses and Progress on TAEUS System in 2023

ENDRA Life Sciences announced its 2023 financial results, highlighting reduced operating expenses and net losses, along with progress in the clinical evaluation and regulatory process for its TAEUS system.

Summary

• ENDRA Life Sciences reported its financial results for the fourth quarter and full year of 2023, showing a decrease in both operating expenses and net losses compared to 2022.
• Operating expenses for the fourth quarter of 2023 were $1.5 million, down from $3.3 million in the same period of 2022, and full-year operating expenses decreased to $10.5 million from $13.2 million in the previous year.
• The net loss for the fourth quarter of 2023 was $1.5 million, or $0.17 per share, compared to a net loss of $3.3 million, or $1.04 per share, in the fourth quarter of 2022.
• For the full year 2023, the net loss was $10.1 million, or $1.58 per share, compared to a net loss of $13.2 million, or $4.56 per share, in 2022.
• The company's cash and cash equivalents stood at $2.8 million as of December 31, 2023.
• ENDRA installed its first TAEUS system in the UK at King's College Hospital for clinical evaluation, with a study planned to include approximately 75 subjects to compare its liver fat assessment accuracy with MRI.
• The FDA review of ENDRA's De Novo request for its TAEUS liver system is ongoing, with an in-person meeting scheduled for the second quarter of 2024.
• ENDRA expanded its intellectual property portfolio to 75 issued patents globally, including seven new patents in the fourth quarter of 2023.
• A new ICD-10-CM code was issued for NAFLD, which ENDRA believes will facilitate standardized billing and promote the integration of advanced diagnostic technologies like TAEUS.

Sentiment

Score: 7

Explanation: The document shows positive progress in clinical trials and regulatory processes, along with improved financial metrics. However, the company's reliance on future capital raises and the ongoing FDA review process temper the overall sentiment.

Positives

• Operating expenses decreased significantly, indicating improved cost management.
• Net losses were reduced both in the fourth quarter and for the full year, showing progress towards profitability.
• The installation of the first TAEUS system in the UK marks a significant step in clinical evaluation.
• The scheduled in-person meeting with the FDA is a positive development in the regulatory process.
• The expansion of the patent portfolio enhances the company's intellectual property value.
• The new ICD-10-CM code for NAFLD is expected to facilitate the adoption of the TAEUS system.

Negatives

• The company's cash and cash equivalents are relatively low at $2.8 million as of December 31, 2023.
• The FDA review process is ongoing, and there is no guarantee of approval.
• The company is still experiencing net losses, indicating it is not yet profitable.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• There is a risk that the company may not obtain the necessary regulatory approvals for its medical devices.
• The company's success depends on the market acceptance of its technology and its ability to compete effectively.
• The company is dependent on third parties for the design and manufacture of its products.
• The company's intellectual property may not be adequately protected.

Future Outlook

ENDRA expects to activate additional clinical evaluation sites in Europe and North America in 2024 to gather more data and gain traction with potential customers. The company also anticipates advancing the regulatory process with the FDA.

Management Comments

• Francois Michelon, Chairman and CEO, stated that there is accelerating momentum in the marketplace for a non-invasive diagnostic tool to assess liver fat like the TAEUS system.
• Michelon also mentioned that the company continues to collaborate with the FDA and looks forward to advancing the regulatory process.

Industry Context

The announcement comes at a time when there is increasing focus on non-alcoholic fatty liver disease (NAFLD) and its more severe form, MASH, with the recent approval of the first therapeutic for MASH and updated guidelines that include screening for fatty liver in at-risk populations. The new ICD-10-CM code for NAFLD also supports the need for better diagnostic tools.

Comparison to Industry Standards

• The company's focus on non-invasive liver fat assessment aligns with the growing trend in the medical device industry towards less invasive diagnostic methods.
• The TAEUS system's claim of being 1/50th the cost of an MRI could position it as a cost-effective alternative, potentially disrupting the market for liver diagnostics.
• Companies like FibroScan (Echosens) offer non-invasive liver assessment tools, but ENDRA's TAEUS technology uses a different approach, potentially offering unique advantages.
• The clinical study at King's College Hospital will provide crucial data to compare the TAEUS system's accuracy with MRI, a gold standard in liver imaging, which will be important for market acceptance.

Stakeholder Impact

• Shareholders may view the reduced losses and progress in clinical trials positively.
• Employees may be encouraged by the company's progress and future prospects.
• Healthcare providers may be interested in the potential of the TAEUS system as a cost-effective diagnostic tool.
• Patients may benefit from the availability of a less expensive and non-invasive method for liver fat assessment.

Next Steps

• ENDRA will continue to collaborate with the FDA to advance the regulatory process.
• The company plans to activate additional clinical evaluation sites in Europe and North America.
• ENDRA will continue to explore licensing opportunities for its intellectual property.

Key Dates

Keywords

TAEUS, Liver Fat, NAFLD, MASH, Thermo Acoustic Enhanced Ultrasound, FDA, Clinical Evaluation, Medical Device, Diagnostics, Patents